Navigation Links
WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results
Date:3/12/2008

Full Year Net Revenues up 93.3%; Full Year Net Income up 283.0%

SHANGHAI, China, March 12 /Xinhua-PRNewswire-FirstCall/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), the leading global pharmaceutical, biotechnology and medical device R&D outsourcing company headquartered in Shanghai, China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2007.

Fourth Quarter 2007 Highlights:

Compared to the fourth quarter 2006 results,

-- Total net revenues increased 62.4% to $37.1 million.

-- Net income increased 205.7% to $12.1 million.

-- Non-GAAP net income increased 156.7% to $16.6 million.

-- Diluted earnings per American Depositary Share ("ADS") were $0.17.

Diluted earnings per ADS excluding share-based compensation expenses

(non-GAAP) were $0.23.

Full Year 2007 Highlights:

Compared to full year 2006 results,

-- Total net revenues increased 93.3% to $135.2 million.

-- Net income increased 283.0% to $33.9 million.

-- Non-GAAP net income increased 158.5% to $44.6 million.

-- Diluted earnings per ADS were $0.42. Diluted earnings per ADS

excluding share-based compensation expenses (non-GAAP) were $0.59.

Commenting on the fourth quarter and full year results, Dr. Ge Li, Chairman and Chief Executive Officer of WuXi PharmaTech said, "2007 was an historic year for WuXi, marked by a number of key strategic and tactical milestones. Riding on the rising wave of demand for pharmaceutical and biotechnology R&D outsourcing services, our business experienced phenomenal growth, with revenues for the year at $135 million, up 93% from 2006, attributable to a strong performance across both
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. WuXi PharmaTech Schedules Fourth Quarter and Full Year 2007 Earnings Release on Wednesday, March 12, 2008
2. WuXi PharmaTech Completes Acquisition of AppTec
3. Quest PharmaTech and BC Cancer Agency to Develop Immuno Photodynamic Therapies for Lung Cancer
4. WuXi PharmaTech (NYSE: WX) CEO Honored among the 2007 China Top 10 Influential Entrepreneurs
5. WuXi PharmaTech to Acquire AppTec Laboratory Services, Inc.
6. WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO
7. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
8. Massachusetts Governor Deval L. Patrick Pays Visit to WuXi PharmaTech
9. WuXi PharmaTech (NYSE: WX) Ranked the 28th of Deloitte Technology Fast 50 China
10. WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia
11. WuXi PharmaTech Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... June 18, 2013 Demanding industrial and ... engineered of synthetic Sapphire and Glass Ball Lenses, now ... Swiss Jewel Company , of Philadelphia , PA. ... and collimating the light beams without the need for ... and natural durability (9 mohs) make it the ideal ...
(Date:6/18/2013)... 18, 2013 RegeneCure announced ...  proprietary AMCA Guided Bone Regeneration (GBR) Dental Membrane as a ... A common problem encountered when patients have a tooth replaced ... volume to house the implant. Consequently there is often a ... the natural bone regenerates. The bone substitute material, in turn, ...
(Date:6/18/2013)... , June 18, 2013  AMRI (NASDAQ: ... Burlington, Mass. , site has ... Enforcement Administration (DEA) registration to handle Schedule 2 ... DEA,s acknowledgement of Burlington,s ... and documentation. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ...
(Date:6/18/2013)... June 18, 2013 This webinar ... pharmaceutical advertising and promotion, and review the basic ... learn how to apply these principles through real ... ,     The fundamentals on FDA regulations and ... labeling ,     Assessing traditional and newer forms ...
Breaking Biology Technology:Swiss Jewel Introduces the Crown Jewels of Fiber-Optic Connectors 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 2RegeneCure Starts Clinical Study Using Polymeric Bone Stimulating Membrane for Dental Implants 3AMRI Burlington Receives DEA Approval to Handle Controlled Substances 2Drug Advertising and Promotion Labeling: FDA Regulations, New Webinar Hosted by Xtalks 2
... Novocell, Inc. , a preclinical stage diabetes ... award totaling $20 million from the California Institute for Regenerative ... scientists at the University of California, San Francisco (UCSF), led ... million. The funding will advance Novocell,s development of a first ...
... Nev., Oct. 28 PDL BioPharma, Inc. (PDL) (Nasdaq: ... a $300 million securitization transaction intended to monetize certain ... closing of the transaction, which is expected to occur ... QHP Royalty Sub LLC ("QHP"), a newly-formed wholly-owned subsidiary ...
... Novavax, Inc. (Nasdaq: NVAX ) announced ... joint venture between Cadila Pharmaceuticals in India, has ... will be used to produce pandemic and seasonal ... virus-like particle (VLP) vaccine technology to produce commercial-scale ...
Cached Biology Technology:Novocell Receives a Disease Team Award for $20 Million from the California Institute for Regenerative Medicine to Develop a Stem Cell Therapy for the Treatment of Diabetes 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 2PDL BioPharma Announces Pricing of $300,000,000 Securitization Transaction 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 2Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 3Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 4Novavax and CPL Biologicals Break Ground on New Influenza Vaccine Manufacturing Facility in India 5
(Date:6/18/2013)... expecting a very large "dead zone" in the Gulf ... in the Chesapeake Bay this year, based on several ... of Michigan, Louisiana State University, and the Louisiana ... of Mexico hypoxic "dead" zone will be between 7,286 ... the ten largest recorded. That would range from an ...
(Date:6/18/2013)... awarded $12.7 million to match nine academic research ... to explore new treatments for patients in eight ... and schizophrenia. The collaborative pilot initiative, called Discovering ... by the National Center for Advancing Translational Sciences ... , The process of developing a new therapeutic ...
(Date:6/18/2013)... Bethesda, MD, June 18, 2013: The Association for Molecular ... Federation of American Societies for Experimental Biology (FASEB) on ... for membership on June 3, 2013. , The ... individuals and share a common vision for the advancement ... "Basic biomedical and translational research is more important now ...
Breaking Biology News(10 mins):NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 2NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 3NOAA, partners predict possible record-setting deadzone for Gulf of Mexico 4NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4
... sites of fundamental geodynamic, geochemical and biological processes and ... for us. Scientific marine drilling and coring is crucial ... (sub-) seafloors to advance our knowledge in the Earth ... (ESF) European Collaborative Research (EUROCORES) programme EuroMARC is an ...
... Calif., November 23, 2008 -- Peregrine Pharmaceuticals, Inc. ... Nature Medicine that supports the broad ... antibody platform, showing that its PS-targeting drug bavituximab ... models. Bavituximab is in clinical ...
... Futronic Technology Company Limited, a,global provider of ... of FS22, a high performance fingerprint access and,attendance ... launched,FS21M (mid-range device) and FS20 (low cost device), ... and attendance control device.,FS22 uses a powerful Digital ...
Cached Biology News:Europe cores in EUROCORES: Ocean drilling in EuroMARC 2Europe cores in EUROCORES: Ocean drilling in EuroMARC 3Europe cores in EUROCORES: Ocean drilling in EuroMARC 4Europe cores in EUROCORES: Ocean drilling in EuroMARC 5Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 2Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections 3Futronic Launches FS22 Fingerprint Access Control Device 2
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
1, 2 or 8 PreMixes are included as part of the FailSafe™ PCR System....
Request Info...
... Nuclease catalyzes the degradation of single-stranded DNA ... products. While the nuclease prefers ssDNA over ... the enzyme degrades double-stranded DNA from both ... used for transcript mapping studies (3,4), for ...
Biology Products: